Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HLCS | P50747 | 3/20 | 0.71 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.71 |
| ▸ | CNR1 | P21554 | 2/20 | 0.64 |
| ▸ | CNR2 | P34972 | 2/20 | 0.62 |
| ▸ | F2 | P00734 | 1/20 | 0.61 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.61 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.61 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.61 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | ABL1 | P00519 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | PKM | P14618 | 1/20 | 0.61 |
| ▸ | IDE | P14735 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | PLCD1 | P51178 | 1/20 | 0.60 |
| ▸ | CA12 | O43570 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13045403 | 1.00 | HLCS (0.71) | HLCSTDP1CNR1CNR2F2 | |
| SCHEMBL15870672 | 1.00 | HLCS (0.71) | HLCSTDP1CNR1CNR2F2 | |
| SCHEMBL7376597 | 1.00 | HLCS (0.71) | HLCSTDP1CNR1CNR2F2 | |
| SCHEMBL12320610 | 1.00 | HLCS (0.71) | HLCSTDP1CNR1CNR2F2 | |
| SCHEMBL22493325 | 1.00 | HLCS (0.71) | HLCSTDP1CNR1CNR2F2 | |
| SCHEMBL8240579 | 0.99 | TDP1 (0.72) | HLCSTDP1CNR1CNR2F2 | |
| SCHEMBL17704089 | 0.99 | TDP1 (0.72) | HLCSTDP1CNR1CNR2F2 | |
| SCHEMBL6941477 | 0.99 | TDP1 (0.72) | HLCSTDP1CNR1CNR2F2 | |
| SCHEMBL18513310 | 0.96 | TDP1 (0.66) | HLCSTDP1CNR1CNR2F2 | |
| SCHEMBL17881931 | 0.96 | TDP1 (0.71) | HLCSTDP1CNR1CNR2F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9844764-B2 | Protein or peptide printing method, protein array or peptide array, and functional protein or functional peptide identification method | UNIVERSITY OF TOKYO (JP) | 2017-12-19 | — | — | US | disclosed |
| US-9493444-B2 | Azaheterocyclic compounds | MERCK PATENT GMBH (DE) | 2016-11-15 | — | — | US | disclosed |
| US-20150005294-A1 | AZAHETEROCYCLIC COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2015-01-01 | — | — | US | disclosed |
| US-8293725-B2 | Peptidomimetic inhibitors of PSMA, compounds comprising them, and methods of use | CANCER TARGETED TECHNOLOGY LLC (US) | 2012-10-23 | — | — | US | disclosed |
| US-8293725-B2 | Peptidomimetic inhibitors of PSMA, compounds comprising them, and methods of use | CANCER TARGETED TECHNOLOGY LLC (US) | 2012-10-23 | — | — | US | disclosed |
| US-RE42275-E1 | Peptidomimetic inhibitors of PSMA, compounds comprising them, and methods of use | CANCER TARGETED TECHNOLOGY LLC (US) | 2011-04-05 | — | — | US | disclosed |
| US-RE42275-E1 | Peptidomimetic inhibitors of PSMA, compounds comprising them, and methods of use | CANCER TARGETED TECHNOLOGY LLC (US) | 2011-04-05 | — | — | US | disclosed |
| US-20100183517-A1 | Peptidomimetic Inhibitors Of PSMA, Compounds Comprising Them, And Methods Of Use | CANCER TARGETED TECHNOLOGY LLC (US) | 2010-07-22 | — | — | US | disclosed |
| US-20100183517-A1 | Peptidomimetic Inhibitors Of PSMA, Compounds Comprising Them, And Methods Of Use | CANCER TARGETED TECHNOLOGY LLC (US) | 2010-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100183517-A1 | Peptidomimetic Inhibitors Of PSMA, Compounds Comprising Them, And Methods Of Use | FOLH1, PSMA1, DNPEP | HLCS 2202/4885TDP1 4028/4885CNR1 4373/4885 |
| US-20150005294-A1 | AZAHETEROCYCLIC COMPOUNDS | PCNA, CDKN1A, CCNC | HLCS 1165/4885TDP1 1163/4885CNR1 2145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.